| Course | NU684 Obstetrical Care |
|---|---|
| Unit | Unit 2 |
| Paper type | Antibody screen interpretation paper |
| Length | About 1,160 words, 7 pages double-spaced |
| Format | APA 7 student paper |
| School | Purdue University Global |
| Program | MSN |
| Updated | October 2026 |
Free sample paper for NU684 Unit 2
An Anti-D Titer of 1:2 at Thirty-Four Weeks: A Unit 2 Antibody Screen Interpretation Paper on Passive Antibody Versus Alloimmunization
[Student Name]
Purdue University Global
NU684: Obstetrical Care
Unit 2 Antibody Screen Interpretation Paper
[Instructor Name]
[Date]
The patient and laboratory values are composite and illustrative; the sources cited are real.
The Situation
Ms. Abiodun is gravida 2, para 1, at 34 weeks 2 days. She is blood group O and Rh D-negative. In her first pregnancy, three years ago, her antibody screen was negative throughout, her son typed Rh D-positive, and the postpartum dose was given on day two. In this pregnancy her first-trimester antibody screen was negative, and she received 300 micrograms of Rh immune globulin at 28 weeks 1 day, six weeks ago.
Yesterday she was the restrained driver in a low-speed collision. She has mild seat-belt tenderness, no bleeding, no contractions and no abdominal pain. Fetal monitoring for four hours was reassuring. The trauma panel included an antibody screen, which detected anti-D, titered at 1:2.
Two Explanations
A positive anti-D screen in an Rh D-negative pregnant patient has two possible meanings, and their management is entirely different.
Passive anti-D is the antibody from Rh immune globulin itself. The injection works by supplying anti-D that clears any fetal Rh-positive red cells before the mother's immune system can respond, and that injected antibody remains detectable in her blood for weeks. ACOG notes that passive anti-D after a standard dose typically produces low titers and that its presence does not mean she is sensitized (American College of Obstetricians and Gynecologists [ACOG], 2017).
Alloimmunization is the mother's own antibody, produced after exposure to Rh-positive fetal cells. It can cross the placenta and break down the baby's red cells, producing fetal anemia and, after birth, jaundice and anemia in the newborn.
Weighing the Evidence
Every feature of her case points toward passive antibody. The injection was six weeks ago, well within the period when it remains detectable. The titer of 1:2 is in the range expected from a standard dose. Her first-trimester screen was negative, and her previous pregnancy was managed with postpartum Rh immune globulin, which makes earlier sensitization unlikely.
The antibody in her blood is the medicine doing its job, until a rising titer says otherwise.
Two steps confirm the interpretation. The blood bank is asked to review the injection history against the titer, which many laboratories do routinely. And the titer is repeated in two to four weeks. Passive antibody declines over time, with a half-life of roughly three weeks; an antibody the mother is making herself stays the same or rises.
What Would Change the Plan
If the repeat titer rose, she would be managed as alloimmunized. ACOG's guidance on alloimmunization describes a critical titer, commonly 1:16 for anti-D, above which the fetus is at risk of significant anemia (ACOG, 2018). Below it, titers are repeated at intervals; at or above it, the fetus is assessed with Doppler ultrasound of the middle cerebral artery. The peak velocity of blood in that artery rises as the fetus becomes anemic, and a value above 1.5 multiples of the median predicted moderate or severe anemia with high sensitivity in the study that established the method (Mari et al., 2000). That approach replaced repeated amniocentesis for most patients.
Fetal Rh D genotyping from cell-free DNA in the mother's blood can also show whether the baby is Rh D-negative, in which case the baby is not at risk regardless of the mother's antibody. ACOG (2018) recognizes this testing as an option where available.
What the Accident Requires
The more pressing issue is not the antibody but the collision. Abdominal trauma can cause fetal blood to enter the maternal circulation, which in an Rh D-negative patient creates a new sensitizing exposure. ACOG (2017) recommends Rh immune globulin after abdominal trauma and quantification of fetomaternal hemorrhage, with additional doses if the bleed is larger than one vial covers. A standard 300-microgram dose protects against about 30 milliliters of fetal whole blood.
Her Kleihauer-Betke test estimates a fetomaternal hemorrhage of about 6 milliliters, within the protection of one dose. Because six weeks have passed since her 28-week injection and the trauma is a new exposure, she receives another 300 micrograms today. The passive antibody already present does not make this unnecessary.
Orders and Next Steps
Five steps follow from the interpretation. To begin, she receives 300 micrograms of Rh immune globulin today for the trauma exposure. Second, the antibody titer is repeated in three weeks, at about 37 weeks, and the blood bank is told about both injections so it can read the result correctly. Third, if the repeat titer has fallen or stayed low, routine care continues; if it has risen, she is referred to maternal-fetal medicine for middle cerebral artery Doppler assessment and the pregnancy is managed as alloimmunized.
Fourth, the baby's blood type is tested at birth. If the baby is Rh D-positive, she receives Rh immune globulin within the usual 72-hour window, even if passive anti-D is still detectable, because its presence is not a reason to withhold the postpartum dose. Fifth, she is told to report decreased fetal movement, vaginal bleeding, leaking fluid, contractions or worsening abdominal pain in the days after the accident, since placental abruption can appear after a delay.
Why Not Assume the Worst?
It might seem safer to treat every positive anti-D screen as alloimmunization and start Doppler surveillance at once. That approach has costs. It sends a patient for repeated specialist scans she does not need, adds weeks of worry and can lead clinicians to withhold postpartum Rh immune globulin on the mistaken belief that she is already sensitized, which would leave her truly unprotected in a future pregnancy. Interpreting the result in context, and confirming it with a repeat titer, protects her better than reflexive escalation.
Explaining It to Her
Ms. Abiodun was frightened by the word "antibody," which she had read could harm the baby. She was told that the antibody most likely came from the injection she received six weeks ago, that it is a sign the injection is working, and that a repeat test will confirm this. She was also told why she needs another injection after the accident, even though she already has antibody in her blood.
Documentation
The note records both Rh immune globulin doses with dates, the titer, the Kleihauer-Betke result, the interpretation as probable passive antibody and the plan for the repeat titer, so that the labor team and the blood bank will interpret the result the same way.
Conclusion
A positive anti-D screen in an Rh D-negative patient is not automatically alloimmunization. In Ms. Abiodun's case, the timing of her Rh immune globulin, the low titer and her earlier negative screen point to passive antibody, which a falling repeat titer will confirm. The accident is the real risk, and it is managed with a new dose of Rh immune globulin sized to the measured fetomaternal hemorrhage.
References
American College of Obstetricians and Gynecologists. (2017). Practice bulletin no. 181: Prevention of Rh D alloimmunization. Obstetrics & Gynecology, 130(2), e57-e70. https://doi.org/10.1097/AOG.0000000000002232
American College of Obstetricians and Gynecologists. (2018). ACOG practice bulletin no. 192: Management of alloimmunization during pregnancy. Obstetrics & Gynecology, 131(3), e82-e90. https://doi.org/10.1097/AOG.0000000000002528
Mari, G., Deter, R. L., Carpenter, R. L., Rahman, F., Zimmerman, R., Moise, K. J., Dorman, K. F., Ludomirsky, A., Gonzalez, R., Gomez, R., Oz, U., Detti, L., Copel, J. A., Bahado-Singh, R., Berry, S., Martinez-Poyer, J., & Blackwell, S. C. (2000). Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. New England Journal of Medicine, 342(1), 9-14. https://doi.org/10.1056/NEJM200001063420102
Reading the NU 684 Unit 2 instructions
Unit 2 usually presents a laboratory result in pregnancy that needs interpretation before any action, often a positive antibody screen, and asks what it means and what happens next. Prompts commonly want the possible explanations, the evidence that favors one, the test or interval that would confirm it, the plan if the other explanation proves true, and patient counseling. Instructors look for students who read the result in context, especially the timing of any Rh immune globulin, rather than reacting to the word "positive." When the scenario includes trauma or bleeding, the prompt usually expects a fetomaternal hemorrhage assessment and dosing. Most sections expect citations to ACOG's practice bulletins on Rh prevention and on alloimmunization, plus the study that established Doppler surveillance or a review of it. Documentation for the blood bank and labor team is often part of the plan.
Inside the NU684 Unit 2 example
The Abiodun paper sets out her blood type, her first pregnancy, both injection dates and the accident before mentioning the antibody. It then defines passive antibody and alloimmunization in two short paragraphs, citing ACOG's Rh prevention bulletin. The evidence section weighs timing, titer and her earlier negative screen, under a highlighted line about the medicine doing its job, and a margin note marks the repeat titer as the deciding test. The contingency paragraph covers critical titers and middle cerebral artery Doppler from Mari and colleagues, and fetal genotyping. The accident section, flagged by a second note, quantifies fetomaternal hemorrhage and gives a new dose. Five next steps follow in prose, and a section explains why assuming the worst would harm her. Counseling and documentation close the paper.
Where the points sit in the NU684 Unit 2 rubric
Interpretation papers in this unit are judged on accurate reasoning about the result, use of the history, a confirming step, contingency planning, management of any new exposure and communication. Accuracy requires distinguishing passive from active antibody with reasons drawn from timing and titer. Use of history earns credit when the paper notes earlier screens and doses rather than treating the result in isolation. A confirming step, such as a timed repeat titer, turns interpretation into a plan. Contingency planning is scored on whether the paper explains critical titers and Doppler surveillance should the antibody prove real. Graders also check that trauma is handled with fetomaternal hemorrhage testing and dosing, and that postpartum prophylaxis is not withheld. Clear patient explanation and documentation for the blood bank complete the clinical criteria, with APA references to both practice bulletins and the Doppler study.
NU684 Unit 2 help: mistakes that cost points
Papers most often lose marks by declaring alloimmunization from a single positive screen without checking when Rh immune globulin was given. Another common error is concluding that a patient with passive anti-D does not need further doses, either after trauma or after birth, which leaves her unprotected. Some papers skip the fetomaternal hemorrhage test after an accident or give a dose without explaining what it covers. Others describe Doppler surveillance vaguely, without the threshold that prompts referral. Counseling that repeats the word "antibody" without explaining it can frighten a patient unnecessarily. Begin by listing every Rh immune globulin dose with its date, then compare the titer with what a passive antibody would produce. Plan the repeat test before anything else. Send your case and laboratory results, and an interpretation paper can be built on that timeline.
Get an NU684 Unit 2 example written to your instructions
Send the case, the antibody results and history of any Rh immune globulin, with the paper instructions and rubric. A custom paper interprets the result, decides between monitoring and reassurance and sets the testing schedule. Turnaround is 24-48h, free the first time. The paper above is an original model document written by our desk, not a submitted student paper and not an official Purdue University Global document.
More NU684 papers and MSN samples
- NU684 Unit 1: Levels of Maternal Care Post
- NU684 Unit 3: Psychosocial Care Plan
- NU684 Unit 4: Seminar Reflection
- NU684 Unit 5: Complication Case Analysis
- NU684 Unit 6: Twin Pregnancy Care Plan
- NU684 Unit 7: Management Plan
- NU684 Unit 8: Induction Plan
- NU684 Unit 9: Postpartum Infection Case Analysis
- NU684 Unit 10: Equity Improvement Proposal
- MN501 Unit 2: Role Analysis Paper
- NU682 Unit 2: Pregnancy Dating Paper
- MN502 Unit 2: Philosophy of Nursing Statement
- NU680 Unit 2: Amenorrhea Workup Paper
NU684 Unit 2 questions, answered
Can Rh immune globulin cause a positive antibody screen?
Yes. After a dose, passive anti-D can be detected for weeks, usually at a low titer. A paper should explain how to tell it from true alloimmunization.
What titer is considered critical?
For anti-D, many centers use 1:16, though laboratories set their own thresholds. A titer at or above it leads to fetal assessment with middle cerebral artery Doppler.
Does the father's blood type matter?
Yes. If the father does not carry the antigen, the baby is not at risk. If he may, fetal antigen testing from maternal blood or amniocentesis can clarify.
Where can I find a free NU684 Unit 2 sample paper?
This page carries the complete NU684 Unit 2 antibody screen interpretation paper. It reads an anti-D titer of 1:2 in a composite Rh D-negative patient against her recent Rh immune globulin, plans a confirming titer and manages a new exposure after a car accident.
Does passive anti-D mean the NU684 Unit 2 patient can skip Rh immune globulin after birth?
No. Passive antibody from an earlier injection fades over weeks and does not protect against exposure at birth. If her baby is Rh D-positive, she still receives the postpartum dose within 72 hours.